Characteristics of Oral Corticosteroid Users Among Persons with Asthma on GINA Step 3 Therapy and Above: A Cross-Sectional Study in Portuguese Community Pharmacies
Open Access
- 9 November 2022
- journal article
- research article
- Published by Taylor & Francis in Journal of Asthma and Allergy
- Vol. ume 15, 1579-1592
Abstract
Purpose: Oral corticosteroids (OCS) are frequently used in asthma management but have an important risk-profile. The aim of the study is to characterize and compare the sociodemographic and clinical characteristics, treatment regimen and asthma control between OCS users and non-users among the population of asthma patients (≥ 18 years) at GINA step 3 and above treated with a fixed combination of an inhaled corticosteroid and a long-acting beta-agonist (ICS/LABA). Methods: Cross-sectional study in Portuguese community pharmacies. Data was collected via paper-based interview delivered at the pharmacy (sociodemographic characteristics and asthma treatment regimen, namely ICS/LABA and OCS utilization), followed by a telephonic interview collecting smoking history, comorbidities, body mass index (BMI), history of exacerbations and asthma-related healthcare resource utilization (HCRU) in the previous 12 months, as well as asthma control using the Control of Allergic Rhinitis and Asthma Test (CARAT®). Results: A total of 347 patients recruited in 98 pharmacies were included in the analysis. Of those, 328 had completed both questionnaires. A quarter of the individuals reported OCS use in the previous 12 months (OCS users), either as add-on therapy (6%) or exacerbation treatment (19%). Patients were mostly females (72%), with an average age of 59.5 years (SD=15.4). OCS users were significantly older and reported more frequently having conjunctivitis (25.9% vs 15.0%), osteoporosis (25.9% vs 13.4%), arthritis (14.6% vs 6.9%), and gastrointestinal disease (16.1% vs 8.1%). OCS users also reported greater urgent HCRU: unscheduled consultations (33.3% vs 9.3%) and emergency department (ED) visits (32.1% vs 12.1%). Both groups presented poor disease control (85.2% of OCS users vs 72.9% of non-OCS users). Conclusion: These results highlight the burden of OCS therapy to asthma patients and the need to improve asthma management, by adopting OCS sparing strategies in this subgroup of patients.Keywords
This publication has 57 references indexed in Scilit:
- Conventional epidemiology underestimates the incidence of asthma and wheeze‐a longitudinal population‐based study among teenagersClinical and Translational Allergy, 2012
- Prevalence of asthma in Portugal ‐ The Portuguese National Asthma SurveyClinical and Translational Allergy, 2012
- Asthma in an Urban Population in Portugal: A prevalence studyBMC Public Health, 2011
- Validation of a questionnaire (CARAT10) to assess rhinitis and asthma in patients with asthmaAllergy, 2010
- Fluticasone versus placebo for chronic asthma in adults and childrenCochrane Database of Systematic Reviews, 2008
- The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) StatementEpidemiology, 2007
- Beclomethasone versus placebo for chronic asthmaCochrane Database of Systematic Reviews, 2005
- Low-Dose Inhaled Corticosteroids and the Prevention of Death from AsthmaNew England Journal of Medicine, 2000
- Inhaled Corticosteroids for Asthma TherapyChest, 2000
- Effect of Long-term Treatment with an Inhaled Corticosteroid (Budesonide) on Airway Hyperresponsiveness and Clinical Asthma in Nonsteroid-dependent AsthmaticsAmerican Review of Respiratory Disease, 1990